ABSTRACT
Aim To study the biotransformation of gly-cyrrhizin in rat intestine-liver. Methods The in situ vascularly perfused rat intestine-liver model was estab-lished with a validated LC-MS/MS method for assay of the model perfusate glycyrrhizin and glycyrrhetinic acid. Results The steady state intestinal and liver ex-traction ratios in the once-through perfused rat intes-tine-liver model for glycyrrhizin were ( 4. 2 ± 0. 6 )%and (28. 0 ± 3. 0)%, respectively; the first-order ab-sorption rate constant for glycyrrhizin in the recircula-tion of perfusate to the intestine model was ( 0. 33 ± 0. 06 ) min-1;after intraduodenal administration of gly-cyrrhizin,the main active metabolite in was the perfu-sate glycyrrhetinic acid, which was also found in intes-tinal luminal fluids. Conclusions The first-pass effi-cacy of glycyrrhizin is obvious and there is only a small amount of metabolite in the intestinal mucosa cells;gly-cyrrhizin is metabolized by gut bacteria or liver cells af-ter oral administration;the in situ vascularly perfused rat intestine-liver model can be used in glycyrrhizin pharmacokinetic studies.
ABSTRACT
Objective To explore the related risk factors of stroke in progression(SIP)and establish discriminant models to predict the incidence.Methods 31 possible related factors were compared between progressive group(n=110)and non-progressive group(n=336),and the related factors were analyzed in discriminant models.Results Discriminant models were established by 16 factors,including arterial stenosis,OCSP subtype,blood glucose,low density lipoprotion,creatinine,the sign of early cerebral infarction on CT,the temperature increasing and the rapidly decreasing of blood pressure in 48 hours after admittion.The evaluation to the models by interview data and prospective data showed a satisfied result.Conclusion Arterial stenosis,OCSP subtype and other significant factors selected by model will be helpful in prediction of SIP.
ABSTRACT
Aim To establish an analytical method for determination of guanfu base I (GFI) concentration in plasma and investigate its pharmacokinetics in rats. Methods Rats were given a 20 mg?kg~-1 dose intravenously. Blood samples were collected at various times after iv administration. The plasma concentration of GFI was determined by LC-MS. Pharmacokinetic parameters were calculated by 3p97 program.Results The method was linear in the 0.05～20 mg?L~-1 concentration range (r=~0.999 4 ). The recovery of guanfu base I was more than 80%.The intraday and interday precision, expressed as the relative standard deviation (RSD), was generally good (